Palestra "MicroRNAs deregulation in urological tumours: from biology to clinics"
No dia 16 de janeiro, pelas 14h00, irá realizar-se a mais uma palestra do Ciclo Distinguished Seminars, que terá lugar no auditório 1.8.1 do Complexo Pedagógico, do Campus de Gambelas.
Carmen Jerónimo, do IPO Porto, irá proferir a palestra "MicroRNAs deregulation in urological tumours: from biology to clinics".
A entrada é livre.
Sobre a palestra
"The most common genitourinary (GU) neoplasms (i.e., prostate, bladder, and kidney cancers), represent the second most prevalent group of tumours only surpassed by lung cancer. All three are generally clinically silent at their earliest stages, when curative treatment is most likely successful. However, there are no consensual guidelines for GU cancer screening and available methods are characterized by suboptimal sensitivity and specificity. Moreover, standard clinical and pathological parameters meet with important limitations for the assessment of prognosis in an individual basis. An increasing body of evidence is implicating microRNAs (miRs) as driving forces of neoplastic transformation. Our research team has recently identified novel epigenetically regulated onco-suppressor miRs in prostate cancer, controlling processes such as cell cycle, cell viability, invasion potential and cellular senescence. Importantly, in vitro studies showed that restoration of those miRNAs expression attenuated the malignant phenotype of PCa cell lines. Cancer-related miRs alterations are also a source of new cancer biomarkers, intended for early detection, diagnosis and assessment of prognosis. The importance of early diagnosis in Oncology has been emphasized and although current methodologies (such as cytology, histopathology, immunohistochemistry, etc) play a critical role, molecular markers may complement or, eventually, replace them if more effective. Because miRs’ deregulation frequently precede the development of the malignant phenotype, they might enable earlier cancer detection. These miRs are detectable in clinical samples obtained by non- or minimally invasive methods, including biopsy and urine sediments. Moreover, cancer relapse detection before its clinical manifestation (or on imaging during routine patient follow-up) might be accomplished through miR-based biomarkers. In my talk, I will focus on the major findings obtained by our research team regarding miRs implicated in urological tumorigenesis as well as the potential usefulness of miR-based biomarkers for detection and prognostication of these cancers."
